Abstract

Background: The aerobic vaginitis (AV) is characterized by increased levels of aerobic bacteria, vaginal inflammation and depressed levels of lactobacilli. Objective: The purpose of this study was to investigate the therapeutic efficacy of SilTechTM vaginal softgel capsules, containing new microcrystals of silver monovalent ions, for aerobic vaginitis (AV). Methods: This prospective study enrolled 32 women diagnosed with AV. All recruited women were treated with SilTechTM vaginal softgel capsules once daily for 7 days (one course). Therapeutic efficacy was evaluated based on clinical and microscopic criteria, and cure rates were calculated. Women who were improved (but not cured) received a second course of therapy. Patients classified with clinical and microscopic failure were treated using other strategies. Results: After one course of therapy, 59.2% (19/32) of women were cured, 19.0% (6/32) were improved (but not cured) and 21.8% (7/32) failed to respond to the therapy. After two courses of therapy, clinical improvement was achieved in additional two women. The therapy was very well tolerated, and during the entire study no drop out related to the SylTechTM vaginal capsules treatment was observed; only two patients (6.2%) experienced a mild transient burning after application. Conclusion: SylTechTM vaginal capsules is an effective therapeutic option for patients with AV, and most women with AV were cured with one course of therapy.

Highlights

  • The aerobic vaginitis (AV) is characterized by increased levels of aerobic bacteria, vaginal inflammation andHow to cite this paper: Murina, F., Vicariotto, F. and Di Francesco, S. (2016) SilTech: A New Approach to Treat Aerobic Vaginitis

  • Compared with the normal vaginal flora, the aerobes bacteria increased by three to fivefold and were associated with inflamed vaginal mucosa [3]. This condition is often misdiagnosed as bacterial vaginosis, which may lead to treatment failures and severe complications, such as pelvic inflammatory disease, infertility, miscarriage, chorioamnionitis, premature rupture of membranes and preterm delivery [4]

  • Topical treatment with 2% clindamycin resulted in clinical improvement in >95% of women with severe AV, but the recurrence rate was as high as 28.9% [6]

Read more

Summary

Introduction

The aerobic vaginitis (AV) is characterized by increased levels of aerobic bacteria, vaginal inflammation andHow to cite this paper: Murina, F., Vicariotto, F. and Di Francesco, S. (2016) SilTech: A New Approach to Treat Aerobic Vaginitis. Compared with the normal vaginal flora, the aerobes bacteria increased by three to fivefold and were associated with inflamed vaginal mucosa [3] This condition is often misdiagnosed as bacterial vaginosis, which may lead to treatment failures and severe complications, such as pelvic inflammatory disease, infertility, miscarriage, chorioamnionitis, premature rupture of membranes and preterm delivery [4]. Topical treatment with 2% clindamycin resulted in clinical improvement in >95% of women with severe AV, but the recurrence rate was as high as 28.9% [6] We conducted this prospective study to evaluate the efficacy of new SilTechTM vaginal softgel capsules, a new technology capable of driving stabilized silver monovalent ions directly to the site of action, for treatment of AV. Conclusion: SylTechTM vaginal capsules is an effective therapeutic option for patients with AV, and most women with AV were cured with one course of therapy

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.